Zevra Therapeutics (NASDAQ:ZVRA) Reaches New 52-Week High - Still a Buy?

Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Get Free Report) hit a new 52-week high during trading on Wednesday . The stock traded as high as $13.16 and last traded at $12.79, with a volume of 1700798 shares trading hands. The stock had previously closed at $12.79.

Analyst Upgrades and Downgrades

ZVRA has been the subject of several recent research reports. Citigroup reissued an "outperform" rating on shares of Zevra Therapeutics in a research report on Wednesday, May 14th. Cantor Fitzgerald increased their price target on shares of Zevra Therapeutics from $25.00 to $29.00 and gave the company an "overweight" rating in a research note on Thursday, July 10th. HC Wainwright assumed coverage on shares of Zevra Therapeutics in a research note on Wednesday, July 2nd. They issued a "buy" rating and a $26.00 price target for the company. Finally, Wall Street Zen upgraded shares of Zevra Therapeutics from a "buy" rating to a "strong-buy" rating in a research note on Saturday. Eight research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $23.71.

Zevra Therapeutics Trading Down 3.7%

The business's 50 day moving average price is $9.36 and its 200-day moving average price is $8.29. The company has a current ratio of 3.02, a quick ratio of 2.93 and a debt-to-equity ratio of 1.46. The company has a market cap of $673.66 million, a price-to-earnings ratio of -6.48 and a beta of 1.97.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last posted its earnings results on Tuesday, May 13th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.21) by $0.15. The company had revenue of $20.40 million during the quarter, compared to analysts' expectations of $16.96 million. Zevra Therapeutics had a negative net margin of 226.78% and a negative return on equity of 201.05%. During the same quarter last year, the company posted ($0.40) EPS. On average, equities analysts anticipate that Zevra Therapeutics, Inc. will post -1.95 EPS for the current fiscal year.

Institutional Trading of Zevra Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets acquired a new stake in shares of Zevra Therapeutics in the fourth quarter valued at approximately $53,000. GAMMA Investing LLC raised its position in shares of Zevra Therapeutics by 20,564.1% in the first quarter. GAMMA Investing LLC now owns 8,059 shares of the company's stock valued at $60,000 after buying an additional 8,020 shares in the last quarter. Strs Ohio acquired a new position in Zevra Therapeutics in the 1st quarter valued at $125,000. Squarepoint Ops LLC raised its holdings in Zevra Therapeutics by 36.1% in the 4th quarter. Squarepoint Ops LLC now owns 16,534 shares of the company's stock valued at $138,000 after acquiring an additional 4,384 shares in the last quarter. Finally, ProShare Advisors LLC acquired a new position in Zevra Therapeutics in the 4th quarter valued at $145,000. 35.03% of the stock is owned by institutional investors and hedge funds.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.